MAMMA-VAD is officially open — a trial manager's view

MAMMA-VAD is officially open — a trial manager's view

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

I'm delighted to share some good news: MAMMA-VAD officially opened to recruitment on 12 November 2026. After many months of groundwork, our UK-wide breast abscess trial has gone live, and as the trial manager, it feels wonderful to finally write those words. Here's a little about the research behind it, the team I've been lucky enough to join, and how your unit can be part of it.

Why we're running MAMMA-VAD

A breast abscess is a painful pocket of infection in the breast, most commonly occurring during breastfeeding. Many are managed with antibiotics or by draining the fluid using a fine needle. However, larger, deeper or multiloculated abscesses, or those that don't resolve following needle aspiration, are usually referred for surgical drainage, an operation known as incision and drainage.

Our team's earlier national audit, called MAMMA, looked at how units across the UK and Ireland actually treat these abscesses. It found that around one in five patients (21%) underwent surgery, although there was considerable variation between hospitals. Altogether, that adds up to roughly 2,000 operations a year.

Surgery works, but it comes at a cost. It usually requires a general anaesthetic and a prolonged hospital stay, which can separate a new mother from her baby and lead to a switch to stronger intravenous antibiotics. It can also leave scarring and changes to the breast, which patients tell us matter a great deal.

There may be a gentler option. Vacuum-assisted drainage (VAD) uses a wider needle attached to gentle suction to clear the abscess in an outpatient clinic, under local anaesthetic, through a tiny incision (around 5 mm), guided by ultrasound. It can be performed in an outpatient setting without the need for a trip to theatre, and the small wound allows for a quicker recovery. Early case reports and case series have been very encouraging, but VAD has never been tested against surgery in a randomised controlled trial (RCT).

That gap is exactly what MAMMA-VAD sets out to fill: comparing VAD with surgery to establish which approach offers patients a better recovery and experience, while determining whether a larger definitive trial is feasible.

Joining the team

I joined the MAMMA-VAD team at Imperial earlier this year, and I quickly realised how fortunate I was. The trial is led by Professor Daniel Leff, a consultant breast surgeon, and Dr Simon Lowes, a consultant radiologist. I love that the leadership mirrors the trial itself: a surgeon and a radiologist, side by side, genuinely open to the question of which approach serves patients best.

What has struck me most is how they lead. Both have a deep and comprehensive understanding of research, and they provide clear, precise direction so I always know what's expected. At the same time, they encourage me to learn new things and give me room to develop and practise within my scope, while quietly keeping an eye on everything to make sure the trial stays on track. I have also received valuable training and support from the Imperial Clinical Trials Unit (ICTU), while building strong relationships with other trial managers.

As a trial manager, that balance of trust and oversight is exactly what you hope for. It has made the run-up to opening both demanding and genuinely enjoyable.

How the trial works

MAMMA-VAD is a feasibility randomised controlled trial running at up to 26 NHS sites across the UK, aiming to recruit 70 patients. Women who present with a breast abscess that needs surgical draining are invited to take part, and those who agree are randomly allocated on a 1:1 basis to either surgery (incision and drainage, the current standard care) or vacuum-assisted drainage.

We then follow each patient for three months. Our main interest is how satisfied they are with their breast afterwards, measured with a validated questionnaire (modified BREAST-Q), alongside their general quality of life. We also record pain around the procedure, how quickly symptoms settle, whether anyone needs a repeat procedure, antibiotic use, time spent in hospital, and the effect on breastfeeding. To build a more complete picture, we are capturing NHS costs and even the carbon footprint of each pathway, and interviewing patients and clinicians about how acceptable they found the trial.

Where we are now and how your site can join

Getting to 'open' takes a great deal of work behind the scenes. We've secured ethics approval, built and validated all 27 electronic case report forms, set up the database, and prepared the site packs that participating teams need to get started.

Alongside that, we've been reaching out across the country. So far, we've contacted 45 potential sites, with six now in set-up and many more in active discussions about joining. The interest has been hugely encouraging, and breast teams clearly recognise the need for better evidence to guide how we treat these patients.

And this is where you come in and where you can help to improve care. If you work in a breast unit with experience of vacuum-assisted procedures and would like to give your patients the opportunity to be part of answering this important question, we would love to hear from you.

Every site that joins brings us closer to answering a question that genuinely matters to women with breast abscesses and building the evidence for a kinder, less invasive approach to care.

To find out more about taking part, please get in touch with the MAMMA-VAD team. We would be delighted to talk it through with you and your colleagues.

Follow the Topic

Spotlight on Research from the UK
Research Publishing > Spotlight on Research from the UK